Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
An FDA advisory panel voted 7-2 that the benefits of Galleri, a blood test that can screen for multiple cancers at once, outweigh its risks for adults 50 and older. The panel unanimously found it safe, though was split 6-4 on effectiveness, with several members flagging the lack of long-term outcome data. The FDA isn't required to follow the panel's recommendation, but typically does.
An FDA advisory panel gave a cautious thumbs-up to Galleri (Grail Inc.), a first-of-its-kind multicancer early detection (MCED) blood test, voting 7-2 that its benefits outweigh the risks for adults aged 50 and older. The panel unanimously agreed the test is safe, but was more divided on effectiveness (6-4 in favor), with several "yes" voters openly acknowledging uncertainty about long-term clinical benefit. The FDA is not bound by advisory panel recommendations but typically follows them.
Galleri works by detecting cancer-specific methylation patterns in cell-free DNA from a blood sample and is designed to flag cancers — including many with no existing screening test — before symptoms appear. Data from the large PATHFINDER 2 study showed adding Galleri to standard screening produced a 6.5-fold increase in detected cancers, with nearly half caught at stage I or II. However, the pivotal NHS-Galleri randomized trial missed its primary endpoint of reducing late-stage diagnoses.
By the Numbers:
Why it matters: Galleri's potential approval would be a landmark moment — the first MCED test to clear the FDA — and could prompt insurers to cover it. Experts stress it must complement, not replace, standard screening, and that long-term survival data are still needed to confirm it truly improves outcomes.
